Combined aspirin and anticoagulant therapy in patients with atrial fibrillation.
The combined use of aspirin and oral anticoagulant therapy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) has been questioned due to an increased risk of major bleeding with little to no benefit in preventing ischemic events. (1) To better understand patterns and indications for combined antiplatelet and anticoagulant therapy and identify patients who might reasonably be treated with oral anticoagulant (OAC) therapy alone. (2) To perform an updated literature review regarding the use of combined antiplatelet and OAC therapy in patients with AF and stable CAD. Retrospective review. Patients within the University of Cincinnati Health System with a diagnosis of non-valvular AF, excluding those with acute coronary syndrome or revascularization within the last 12 months. Numbers and indications for combined antiplatelet and anticoagulant therapy and sequence of events leading to the initiation of each. Of 948 patients receiving OAC, 430 (45 %) were receiving concomitant OAC and aspirin. Among patients receiving combined antiplatelet and anticoagulant therapy, 49 and 42 % of patients respectively, had CAD or DM. In a more detailed analysis including chart review of 219 patients receiving combined OAC and aspirin, 27 % had a diagnosis of CAD and 14 % had a diagnosis of DM prior to the development of AF. These patients were initially treated with aspirin. Warfarin was added when they subsequently developed AF but aspirin wasn't discontinued. A surprisingly large proportion of patients (22.8 %) had no obvious indication for dual therapy. Prior myocardial infarction, CAD, vascular disease and DM (among others) increase the likelihood of receiving combined antiplatelet and anticoagulant therapy among patients with AF. A literature review suggests this may lead to increased major bleeding with little benefit in decreasing either AF-related stroke or cardiovascular events.
Division of General Internal Medicine and Center for Clinical Effectiveness, University of Cincinnati Medical Center, PO Box 670535, Cincinnati, OH, 45267-0535, USA.
Charlotte H
CH
So
Division of General Internal Medicine and Center for Clinical Effectiveness, University of Cincinnati Medical Center, PO Box 670535, Cincinnati, OH, 45267-0535, USA. mark.eckman@uc.edu.
Mark H
MH
Eckman
D000046:Academic Medical Centers; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D003324:Coronary Artery Disease / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000188:drug therapy; D004359:Drug Therapy, Combination / Q000379:methods* / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D012189:Retrospective Studies; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D014859:Warfarin; D001241:Aspirin
Anticoagulation; Aspirin; Atrial fibrillation; Coronary artery disease; Performance improvement; Warfarin
Am J Med. 2014 Oct;127(10):979-986.e2
24838192
Lancet. 1998 Jan 24;351(9098):233-41
9457092
Ann Intern Med. 2009 Mar 17;150(6):405-10
19293073
Chest. 2012 Feb;141(2 Suppl):e531S-75S
22315271
Ann Intern Med. 2007 Feb 20;146(4):278-88
17310052
Circulation. 2015 Aug 25;132(8):624-32
26106009
Can J Cardiol. 2013 Jul;29(7 Suppl):S60-70
23790600
J Am Coll Cardiol. 2012 Feb 28;59(9):854-5
22361407
Lancet. 2013 Mar 30;381(9872):1107-15
23415013
Arch Intern Med. 2010 Sep 13;170(16):1433-41
20837828
Chest. 2010 Nov;138(5):1093-100
20299623
Arch Intern Med. 2007 Jan 22;167(2):117-24
17242311
N Engl J Med. 2002 Sep 26;347(13):969-74
12324552
Circulation. 2013 Aug 13;128(7):721-8
23861512
Health Technol Assess. 2013 Jul;17(30):1-188
23880057
Chest. 2010 Feb;137(2):263-72
19762550
Am Heart J. 2006 Nov;152(5):967-73
17070169
Diabetes Care. 2016 Jan;39 Suppl 1:S4-5
26696680
Eur Heart J. 2012 Nov;33(21):2719-47
22922413
Chest. 2012 Feb;141(2 Suppl):53S-70S
22315256
J Am Coll Cardiol. 2012 Dec 18;60(24):e44-e164
23182125
Circulation. 2014 Apr 15;129(15):1577-85
24470482
J Am Coll Cardiol. 2014 Oct 7;64(14):1430-6
25277612
Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E266-355
22065485
JAMA. 2001 May 9;285(18):2370-5
11343485